Puma Biotechnology (PBYI)

• Market cap: $179M
• 1 day: -5.90%
• 5 days: -10.43%
• 1 month: 11.30%
• 3 months: 0.30%
• 6 months: 16.32%
• Year to date: 7.37%
• 1 year: 0.90%
• 5 years: -64.92%
• 10 years: -97.42%
• Sector: Healthcare
• Industry: Biotechnology

About: Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Employees: 172

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

1,680% more call options, than puts

Call options by funds: $178K | Put options by funds: $10K

76% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 25

32% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 19

5% more funds holding

Funds holding: 111 [Q4 2024] → 116 (+5) [Q1 2025]

1.43% more ownership

Funds ownership: 59.88% [Q4 2024] → 61.31% (+1.43%) [Q1 2025]

0% more capital invested

Capital invested by funds: $89.7M [Q4 2024] → $90M (+$371K) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]